Call for the design and development of innovative solutions in the area of new pharmaceutical forms of authorized medicinal products, generic drugs and biosimilar drugs

Purpose and object of the call

The purpose of the Call is to provide financial support to manufacturers of medicinal products to carry out research and development work on the design and development of innovative solutions in the area of medicinal products that will lead to the Commercialization of newly developed medicinal products within a maximum of 3 years from the completion of the Project.

It is possible to submit Applications for Projects at different stages of development - both those at the idea stage and Projects requiring only development work, for example.

Deadline for submission of applications

May 31, 2022. - August 31, 2022.

Allocation earmarked for the call

PLN 150 million

Minimum value of the Project

PLN 2 million

Maximum value of a Project

PLN 20 million

Applicants

Applications under the Call may be submitted by both Single Entity Applicants and Consortia. The Single Entity Applicant and Consortium Leader must be an enterprise, and the other members may be entities referred to in Article 17(1) of the Law of February 21, 2019 on the Medical Research Agency (including scientific institutions and medical entities).

The subject of the Call are medicinal products, such as:

- generic drugs,

- biosimilar drugs,
- new pharmaceutical forms of modified release dosage forms,
- new pharmaceutical forms of medicinal products based on authorized active substances,
- fixed combination products.

Funding is provided for:

- basic research,
- industrial research,
- development work,
- additionally, companies in the SME sector may apply for funding for consulting services.

The intensity of funding for individual entities for each type of work in the Project is based on the regulations on the rules of public aid.

Commercialization requirement

Regardless of the initial phase the Project is in, it must end with the implementation of the drug product into serial production within:

- the Beneficiary's own economic activity, or
- as part of a third party's business activity (licensing to a third party by the Beneficiary or sale of rights to a third party by the Beneficiary).

Method of application submission

The application must be submitted only in the form of an electronic document via the ICT System, available on the Agency's website https://konkurs.abm.gov.pl/#/.

Questions regarding the competition should be sent to the following email address: komercyjne@abm.gov.pl.

Previous Page
Next Page